

Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma: An update on generic Protonix® litigation

Mumbai, February 15, 2012: Sun Pharmaceutical Industries Ltd ("Sun Pharma", also together with its subsidiaries) announces that in the ongoing litigation pending in the United States District Court of District of New Jersey ("the District Court") regarding Sun Pharma subsidiary's and Teva's ("defendants") generic pantoprazole products, Wyeth has submitted to the District Court confidential expert reports claiming damages against defendants arising out of defendants earlier at-risk launches. Earlier in 2010, the District Court had denied defendants motion for judgment as a matter of law seeking to reverse the jury verdict that the patent is not invalid. The District Court is yet to rule on patent misuse.

Wyeth's experts have estimated the purported damages from Sun Pharma to be \$ 960 million. Wyeth's experts have also claimed Teva may be liable for some of Sun Pharma's damages and vice versa.

In due course, Sun Pharma will also serve upon the parties Sun Pharma's expert reports providing its own assessment on the purported damages. After this, patent misuse and appropriate level of damages will be determined. Sun Pharma believes that it has sound reasons to disagree with these overstated claims of Wyeth, and also continues to believe that the patent is invalid and unenforceable and will pursue all available legal remedies including appeals.

Protonix® is a registered trademark of Wyeth Pharmaceuticals, Inc.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com